A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
Price : $35 *
At a glance
- Drugs LY 2623091 (Primary) ; Spironolactone; Tadalafil
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 01 Feb 2017 Results (n=294) assessing population pharmacokinetics of LY-2623091 using patients data from this and other four trials (NCT01427972, NCT02242981, NCT01237899), published in the Journal of Clinical Pharmacology
- 30 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.